Literature DB >> 27428759

Donor-Specific Antibodies Are Produced Locally in Ectopic Lymphoid Structures in Cardiac Allografts.

M M H Huibers1, A J Gareau2, J M T Beerthuijzen1, E Siera-de Koning1, J van Kuik1, E G Kamburova3, A Vink1, N de Jonge4, T D G Lee5,6,7, H G Otten3, R A de Weger1.   

Abstract

Cardiac allograft vasculopathy (CAV) is a transplant pathology, limiting graft survival after heart transplantation. CAV arteries are surrounded by ectopic lymphoid structures (ELS) containing B cells and plasma cells. The aim of this study was to characterize the antigenic targets of antibodies produced in ELS. Coronary arteries and surrounding epicardial tissue from 56 transplant recipients were collected during autopsy. Immunofluorescence was used to identify antibody-producing plasma cells. Immunoglobulin levels in tissue lysates were measured by enzyme-linked immunosorbent assay and analyzed for donor-specific HLA antibodies by Luminex assay. Cytokine and receptor expression levels were quantified using quantitative polymerase chain reaction. Plasma cells in ELS were polyclonal and produced IgG and/or IgM antibodies. In epicardial tissue, IgG (p < 0.05) and IgM levels were higher in transplant patients with larger ELS than smaller ELS. In 4 of 21 (19%) patients with ELS, donor-specific HLA type II antibodies were detected locally. Cytokine and receptor expression (CXCR3, interferon γ and TGF-β) was higher in large ELS in the epicardial tissue than in other vessel wall layers, suggesting active recruitment and proliferation of T and B lymphocytes. ELS exhibited active plasma cells producing locally manufactured antibodies that, in some cases, were directed against the donor HLA, potentially mediating rejection with major consequences for the graft. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  B cell biology; alloantibody; heart transplantation/cardiology; molecular biology; pathology/histopathology; rejection: antibody-mediated (ABMR); rejection: chronic; translational research/science; vasculopathy

Mesh:

Substances:

Year:  2016        PMID: 27428759     DOI: 10.1111/ajt.13969

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  11 in total

1.  Mechanisms Underlying Antibody-Mediated Rejection.

Authors:  William Baldwin; Anna Valujskikh
Journal:  Circulation       Date:  2020-02-10       Impact factor: 29.690

2.  B cell clonal expansion within immune infiltrates in human cardiac allograft vasculopathy.

Authors:  Carolina Moore; Baoshan Gao; Krishna M Roskin; Elena-Rodica M Vasilescu; Linda Addonizio; Michael M Givertz; Joren C Madsen; Emmanuel Zorn
Journal:  Am J Transplant       Date:  2019-12-27       Impact factor: 8.086

Review 3.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

Review 4.  Is There a Role for Natural Antibodies in Rejection Following Transplantation?

Authors:  Emmanuel Zorn; Sarah B See
Journal:  Transplantation       Date:  2019-08       Impact factor: 4.939

5.  Prevalence of polyreactive innate clones among graft--infiltrating B cells in human cardiac allograft vasculopathy.

Authors:  Debanjana Chatterjee; Carolina Moore; Baoshan Gao; Kevin J Clerkin; Sarah B See; David Shaked; Kortney Rogers; Sarah Nunez; Yokarla Veras; Linda Addonizio; Michael M Givertz; Yoshifumi Naka; Donna Mancini; Rodica Vasilescu; Charles Marboe; Susan Restaino; Joren C Madsen; Emmanuel Zorn
Journal:  J Heart Lung Transplant       Date:  2017-09-28       Impact factor: 10.247

Review 6.  Memory T Cells in Transplantation: Old Challenges Define New Directions.

Authors:  Michael Nicosia; Robert L Fairchild; Anna Valujskikh
Journal:  Transplantation       Date:  2020-10       Impact factor: 5.385

Review 7.  B Cell Immunity in Solid Organ Transplantation.

Authors:  Gonca E Karahan; Frans H J Claas; Sebastiaan Heidt
Journal:  Front Immunol       Date:  2017-01-10       Impact factor: 7.561

8.  The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis.

Authors:  Dominika Klimczak-Tomaniak; Stefan Roest; Jasper J Brugts; Kadir Caliskan; Isabella Kardys; Felix Zijlstra; Alina A Constantinescu; Jolanda J C Voermans; Jeroen J A van Kampen; Olivier C Manintveld
Journal:  Transplantation       Date:  2020-07       Impact factor: 5.385

Review 9.  Effector B cells in cardiac allograft vasculopathy.

Authors:  Emmanuel Zorn
Journal:  Curr Opin Organ Transplant       Date:  2019-02       Impact factor: 2.640

10.  T cell repertoire analysis suggests a prominent bystander response in human cardiac allograft vasculopathy.

Authors:  Marlena V Habal; April M I Miller; Samhita Rao; Sijie Lin; Aleksandar Obradovic; Mohsen Khosravi-Maharlooei; Sarah B See; Poulomi Roy; Ronzon Shihab; Siu-Hong Ho; Charles C Marboe; Yoshifumi Naka; Koji Takeda; Susan Restaino; Arnold Han; Donna Mancini; Michael Givertz; Joren C Madsen; Megan Sykes; Linda J Addonizio; Maryjane A Farr; Emmanuel Zorn
Journal:  Am J Transplant       Date:  2020-10-26       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.